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A B S T R A C T
Introduction: ; Heparin bonded grafts have proven to improve patency, at least
transiently.
Two diﬀerent heparin bonded expanded polytetraﬂuoroethylene (ePTFE) grafts produced by diﬀerent technologies are currently available.
This pilot primary goal was to test these commonly used, but diﬀerently heparinized ePTFE grafts for diﬀerences in primary patency after a 6-months follow-up in
a sheep model. Secondly, the aim was to establish a large animal model to enable future translational studies and further graft development.
Method: ; End-to-side bypass of the common carotid artery was performed bilaterally in sheep. Either a Gore® Propaten heparinized graft or a Jotec® Flowline Bipore
heparinized graft was used, both 5mm in diameter.
Following graft implantation, the sheep were kept on pasture for 6 months, with monthly duplex scans to determine patency. At termination, the grafts were
duplex scanned a ﬁnal time, with the animals sedated, and the grafts were removed for heparin activity analysis.
Results: ; 14 sheep were operated, 11 survived total follow-up time. At ﬁnal follow-up, 4 patent Gore® grafts, and 6 Jotec® remained. Mean patency time was
106.7 ± 21.9(SD) days and 96.2 ± 25.9(SD) days for Gore® and Jotec®, respectively. Log-rank test showed no signiﬁcant diﬀerence at ﬁnal follow-up after 6
months. Post mortem heparin analysis showed no signiﬁcant diﬀerence in mean activity.
Conclusion: ; Based on patency data alone, no signiﬁcant diﬀerence between these grafts were found. In accordance, heparin activity analysis showed no diﬀerence
between the grafts. The model itself, proved easily implementable, and provides many possibilities for future studies, though some adjustments should be made to
improve survival.
1. Introduction
Revascularization below the knee, is typically done using auto-
logous saphenous veins (ASV), as these are the conduit of choice.
However, recent studies show, that ePTFE grafts bonded with heparin
using the CARMEDA® BioActive Surface (CBAS) process, have com-
parable patency to ASV [1–5]. Below the knee bypass/revascularization
surgery is done to salvage limbs, but stenosis due to neointimal hy-
perplasia (NH) is the most common complication to revascularization
surgery. This is especially true when utilizing artiﬁcial grafts [4].
A Swedish study from 1988 [6] showed heparin had an inhibitory
eﬀect on the formation of NH at the anastomosis site, in addition to the
antithrombotic eﬀect.
Ongoing development have improved the general patency of pros-
thetic grafts, although patency is still lacking compared to that of
autologous vein grafts [1–5,7]. The most recent development has been
bonding heparin covalently to ePTFE grafts to ensure a sustained local
heparin activity and potentially improve patency.
Additionally, risks such as acute hemorrhaging or heparin induced
thrombocytopenia [8,9], associated with continuous heparin adminis-
tration will not be an issue.
A Swedish company, Carmeda, achieved this and consequently pa-
tented their method, which was later purchased by Gore®. The ﬁrst
commercially available graft with CBAS bonded heparin, was released
in 2004, around the same time a animal study showed a reduction in
NH as well as improved patency when compared to crude grafts [10].
This was later conﬁrmed in the Propaten-trial, a multicenter rando-
mized clinical trial, including 11 Scandinavian centers and a total of
569 patients. This showed a signiﬁcantly better overall patency of the
heparinized grafts compared to ordinary PTFE grafts after 1-year
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follow-up [11].
Currently two name brands promote their grafts as being bonded
with heparin. Gore® warrants end-point bound heparin [12], anchoring
the heparin-molecule with the bioactive-site reaching into the lumen of
the graft, supposedly improving patency [11,13,14]. The Jotec® graft is
also marketed as coated with heparin, however Jotec® does not specify
how the heparin molecules are bound, therefore it could bound at
random. This may reduce heparins eﬃciency as an anticoagulant, be-
cause the bio-availability may be reduced when compared to the Gore®
grafts. To our knowledge a study concerning this speciﬁc comparison
was performed by Vermassen et al., in 2009, but so far, no results have
been published [15].
This pilot study's objective was to investigate, the primary patency
rates of these diﬀerently heparin bonded grafts, during a 6 months'
follow-up period. Additionally, remaining heparin activity after 6
months would also be assessed, as well as the feasibility of the animal
model itself.
2. Method and material
2.1. Design
This pilot study's design and experimental animal model was based
on a previous study published by Pedersen et al. [10] using a paired
design with bilateral implantation of grafts bypassing the common
carotid arteries. This study however, directly compares two diﬀerent
Heparin bonded 5mm grafts, as opposed to comparing a crude graft
with a heparinized graft (both 6mm in diameter) as Pedersen et al. did.
Unlike Pedersen et al., we ligated the native common carotid artery
approx. 1 cm distally from the proximal anastomosis, to create turbu-
lent ﬂow that would challenge the antithrombotic nature of the grafts.
The diﬀerent grafts were alternately implanted on the right and left
side by a ﬁxed randomization key.
The study protocol was approved by the Danish animal experiments
inspectorate.
2.2. Materials
The Gore® grafts branded as Propaten® grafts were 5mm in dia-
meter, and removable ring inforcing. They were made from expanded
polytetraﬂuoroethylene, and had their rings removed to better match
the Jotec® grafts. Heparin is bound covalently to the graft surface, by a
proprietary method allowing Gore® to guarantee end-point bonding of
the heparin molecules.
The Jotec® grafts branded as FlowLine Bipore heparin® were also
5mm in diameter and had no ring reinforcement. The grafts were also
made from expanded polytetraﬂuoroethylene. Jotec® markets these
grafts with innovative heparin coating, bound covalently, however
makes no statement as to any speciﬁc binding of the heparin molecules.
2.3. Animals
Sheep were selected, because of their relatively stable body weight
throughout a long follow-up period. Moreover, they usually recover
rapidly following surgery with minimal care from animal technicians
needed. This allows fast transfer from the stables to stay in pastures,
which reduces costs and increases animal welfare.
We used female sheep (n= 14) wild type crossbreeds, but pre-
dominantly of the Texel race, which are usually more docile, thus easier
to handle during duplex-scans without the need for sedation. Mean
weight was 52 kg (range: 36–62 kg), mean age 4.2 years (range: 1–7
years).
2.4. Implantation of the grafts
All operations were done by the same two trained vascular
surgeons, and a medical student assisting them, and during surgery an
animal technician observed the vital parameters of the animal.
The common carotid artery was exposed for this bilaterally, using
standard open surgical technique, exposing approximately 5–10 cm of
the artery, depending on the muscular conﬁguration of the sheep, to
avoid damaging muscles, and the vagus nerve(Fig. 1). Both grafts were
5mm in diameter, and the Gore® graft which was ring-enforced had the
rings removed to make it more comparable to the Jotec® graft.
Before clamping the common carotid artery, 5000 IU Heparin was
administered, to prevent clotting, while suturing the anastomosis.
Graft-ends were cut at a 45-degree angle and anastomosis were done in
end-to-side fashion using 5–0 Prolene (Prolene®, B Braun, Melsungen,
Germany) leaving the grafts approx. 6 cm in length. After conﬁrming
the patency of the anastomosis and the grafts themselves, with palpable
pulse, the native artery was ligated using 2–0 prolene, approx. 1 cm
distally from the proximal anastomosis(Fig. 2). The wound was closed
in two layers, using self-absorbing 2-0 Vicryl (Vicryl®, Ethicon Inc.,
USA).
2.5. Follow-up
All sheep were duplex scanned, with a portable GE Logiq E ultra-
sound device utilizing a linear probe (Fig. 3). Baseline scan was done
two weeks following surgery, and every month following that, for a
complete follow up of 6 months all duplex scans were carried out by the
same operator. This protocol was continued even after an occlusion was
detected.
Additionally, the sheep were also be duplex scanned during sedation
right before sacriﬁcial. Immediately before the sheep were sacriﬁced,
Fig. 1. Preparation of the common carotid artery. A; Common Carotid Artery V;
Jugular vein.
Fig. 2. Final position of Gore® graft, palpable pulse control of patency before
wound closure.
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5000 IE heparin was administered to prevent blood clots in the pros-
thesis, this was done to enable easier in-vitro analysis.
The remaining heparin activity from the removed grafts, after 6
months was analyzed at Carmeda AB laboratories in Stockholm,
Sweden.
2.6. Statistical analysis
Sample size was derived from power calculations, with 0.8 power at
a 0.05 signiﬁcance level and a 0.2 correlation coeﬃcient, which sug-
gested a sample size of 11, but to account for eventual losses 14 sheep
were operated.
Patency for each graft was recorded, in days, and diﬀerence be-
tween grafts was tested using log-rank analysis. Post hoc analysis after 3
months were performed. The diﬀerence in patency was further ana-
lyzed by paired t-test of the diﬀerences in patency's between the in-
dividual paired grafts.
Additionally, survival analysis was graphed as a Kaplan-Meier plot.
Stata/IC version 14 (Statacorp) were used for all analyses and illus-
trations.
The heparin activity was expressed as quantitative results, which
represented the amount of active heparin at removal at the end of
follow up. The diﬀerences between the individual implanted grafts
were compared by paired t-test.
3. Results
3.1. Surgical outcome
14 Sheep were operated, one had to be put down 3 days following
the operation, due to post-operative complications. Another was eu-
thanized after 9 days due to suspected aspiration pneumonia. Lastly one
sheep had a wound defect, resulting in a prosthesis infection, which had
to be removed. The same animal was put down at the ﬁrst monthly
follow-up, possibly due to paralytic bowels syndrome. The remaining
animals did not suﬀer any complications and stayed on pasture for the
entire follow-up period.
3.2. General patency
After 6 months follow up, n= 4 (36.4%) Gore® and n=6 (54.5%)
Jotec® grafts were still patent (Table 1). It should be noted, that the
sheep, which was euthanized due to a wound defect, still had a
functioning Gore® graft.
3.3. Patency in days
Mean patency for the Gore® grafts were 116.4 ± 21.6 (SD) days
compared to Jotec® 104.9 ± 26.7(SD) days. Paired t–test analysis of
the diﬀerence between the pairs of grafts showed no signiﬁcant dif-
ference (p=0.74).
Heparin activity was recorded as picomol/cm2 for each graft. Mean
heparin activity in Gore® grafts was 16.6 pmol/cm2±2.3 (SD), and
15.6 pmol/cm2 ± 4.3 (SD) for the Jotec®. Paired t-test showed no dif-
ference between grafts, with a mean diﬀerence of 1.00 (95% CI -2.64;
4.64), p= 0.554.
The Kaplan-Meier plot (Fig. 6), shows that the Gore® grafts did not
occlude as rapidly as the Jotec® grafts with 6 patent grafts of each make
after three months. However, after this initial period an increasing
number of Gore® graft failures were observed, and at six months’ ﬁnal
follow up, the initially observed diﬀerence between the grafts had di-
minished (p=0.88 by log-rank test) with four remaing patent Gore®
grafts and six Jotec® grafts.
Interestingly, post-hoc analysis, showed that the Gore® grafts, had
signiﬁcantly better patency than the Jotec® grafts until the 3rd month,
were most of the occlusions occurred in both groups (p=0.027 by log-
rank test).
3.4. Visibility
Concerning ultrasonic visibility of the implanted grafts, it is notable
that duplex scans were carried out with the animals un-sedated. This
was done to reduce the stress on the animals, sometimes requiring
operator patience. Depending on the muscular conﬁguration of the
sheep, and how the grafts themselves behaved in-vivo, visibility was
remarkably good, with clear duplex signal (Fig. 4), and in the case of
occlusion, even visible thrombosis (Fig. 5). The animals were sedated
before sacriﬁce, and only 2 duplex-scans diﬀered from the previous
scanning results. Concordantly if a graft was patent at the time of sa-
criﬁce and previous scans had deemed it occluded, it was recorded as a
patent graft throughout the study.
4. Discussion
Heparin bonded grafts have proven to improve patency, at least
transiently [16].
Diﬀerences in heparin bonding to the grafts may inﬂuence the
outcome.
This pilot study demonstrates, as the ﬁrst comparative study, no
immediate signiﬁcant diﬀerence, in primary patency between the tested
grafts at 6 months’ follow-up. However a trend showing a potential
short-term eﬀect is found. Due to the high numbers and long observa-
tion time needed in clinical trials, examining diﬀerent grafts patency is
often done retrospectively in registry studies [1,7], which make a
controlled experimental study like this desirable. This study also paves
the way for future animal studies to investigate novel advancements
into artiﬁcial grafts, as the animal model itself shows great potential.
Concerning our ﬁndings regarding patency, the Kaplan-Meier plot
(Fig. 6) suggest no signiﬁcant (p=0.88) diﬀerence between the grafts
after 6-months follow up.
Nevertheless, there seems to be a trend indicating that initial pa-
tency is better in the Gore® grafts, with n=2 (18.2%) failures at the
time of ﬁrst duplex, compared to n= 4 (36.4%) Jotec®. As previously
shown the crucial point remains at 3 months [10], where many oc-
clusions occur. However, at this point log-rank test still shows a sig-
niﬁcant diﬀerence between the grafts (p= 0.027). This could be due to
the sustained heparin activity in the Gore® grafts, which might protect
the grafts from acute occlusion within the ﬁrst three months. Ad-
ditionally, if our hypothesis is right, it also explains why the Jotec®
Fig. 3. Duplex-scan of sheep.
Table 1
Number of patent grafts at baseline duplex scan – and at 6 month endpoint.
Baseline Endpoint
Gore n=11 9 (81.8%) 4 (36.4%)
Jotec n=11 7 (63.6%) 6 (54.5%)
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grafts occlude earlier on. However, this remains speculative as it was
not planned initially and would require additional heparin analysis, but
it does show an interesting trend.
In comparison with other animal studies investigating heparin
bonded grafts, the occlusion rate of this series is higher than expected
[13,17,18]. This might be partly explained by a smaller diameter of the
grafts used, since comparable studies used 6mm grafts opposed to
5mm in our study, resulting in a 30% decrease in lumen area, in-
creasing the strain on the grafts.
Looking at the removed grafts reported heparin activity, no diﬀer-
ence was found. This corresponds with our survival analysis.
Retrospectively it could have been interesting to perform the heparin
activity analysis both prior to implantation and after explanation.
4.1. Methodological considerations
Our intension was to challenge the bonded heparin and patency of
grafts as much as possible by choosing 5mm grafts and furthermore,
creating turbulent ﬂow by ligation of the native common carotid artery
approximately 1 cm distally from the proximal anastomosis. These
modiﬁcations of the model may have overly encouraged thrombo-
genicity, compared to previous reports [10], [13,17,18]. This might
Fig. 4. Open graft, no turbulent ﬂow or signs of thrombosis.
Fig. 5. Occluded graft, no color signal. Mural thrombosis is clearly visible. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to
the Web version of this article.)
Fig. 6. Kaplan-Meier survival plot of Gore® and Jotec® Grafts. Log-rank
p=0.88 at end-point.
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also contribute to the relative high number of occlusions, which is not
in line with previous retrospective studies with a 70–80% patency rate
in diseased patients [11,14,19]and in contrast to the reported patency
by Pedersen et al.
Additionally, patency studies done in baboons, canines, and sheep
all show better patency in grafts with CBAS immobilized heparin [10],
[13,17,18], than what this study reports.
If a larger diameter graft had been used, there might have been a
clearer diﬀerence between the grafts, than in this current setup. The
strain on the grafts in our series, might censor the actual diﬀerence
between the grafts.
It could be argued that antiplatelet therapy, which ought always to
be administered to patients with known atherosclerotic disease, would
improve the patency of these grafts as shown by an arteriovenous-graft
model in porcine [17]. However, the interest of this study is purely in
the anti-thrombotic abilities of the grafts themselves. Which is why
antiplatelet therapy, was not included in this current series.
4.2. Study limitations
In our series, there were some early censoring of the grafts, fol-
lowing the complications mentioned above. These could have been due
to surgery, although all surgical procedures were performed proﬁcient,
and up to clinical standards. One graft however, did get infected most
likely because of a wound defect, and not because surgical aseptic
failure.
Considering that three out of all 14 (21.4%) sheep did not live
through the length of the study, this is of course a disadvantage to the
series, but on the other hand, the required sample size was achieved.
Another limitation of this series, and potentially in any series using
sheep, is that their atherosclerotic status, is unknown, if there is any.
This could have potential implications when using data derived from
sheep studies, when treating patients.
It is still too early to reach a conclusion concerning the diﬀerences
in primary patency between these two types of heparinized grafts.
Mainly because our model might have challenged the grafts to a clini-
cally irrelevant level. But this could probably be avoided using a larger
diameter graft in a future series. It could also be argued that the grafts
could be interpositioned with end-to-end anastomosis instead of end-to-
side, to reduce the strain on the grafts, when testing the antithrombotic
capabilities. But this would not reproduce real-world conditions for
most below knee bypasses.
4.3. Clinical implications
This study, has continued the foundation of earlier animal studies,
to create a large model that allows a direct comparison of grafts.
This large animal model makes a direct comparison a real possibi-
lity. We are now able to compare the eﬀects of these modern grafts in-
vivo, which provides us with an extended evidence base to choose the
best treatment available for patients.
Regarding the patency results, more research is still required. This
could be done using a graft size which is more commonly used in re-
vascularization surgery, i.e. a 6mm graft. This might reduce the strain
on the grafts, and therefore provide a more accurate result. A future
study could include a 3-month end-point, were grafts would be re-
moved for heparin analysis, since it seems that most occlusions occur
around this point in time.
This study model shows promise to enable future studies to be
conducted investigating the future development of artiﬁcial vascular
grafts. It could even be adapted to feature an infection model, that
could test grafts for their ability to ﬁght of infections, or timed drug
release.
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